Stocks · News reference
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $685 to $687.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 6:47 PM
- Checked
- Jul 23, 2026, 6:47 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its
Read original at benzingaRBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.
Read original at benzinga8-K filing — UNITED THERAPEUTICS Corp (UTHR)
Filed: 2026-08-05 AccNo: 0001082554-26-000028 Size: 432 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar